Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 87 of 87 results for hepatitis c

  1. New drugs 'a major benefit' for patients with chronic hepatitis C

    NICE has recommended the use of boceprevir (Victrelis) and telaprevir (Incivo), both in combination with peginterferon alfa and ribavirin, as options for the treatment of the most common strain of hepatitis C in adults, in latest guidance.

    News
    Published
    25 April 2012

  2. Telaprevir for the treatment of genotype 1 chronic hepatitis C (TA252)

    Telaprevir no longer has a marketing authorisation in the UK so this guidance has been withdrawn.

    Technology appraisal guidance
    Published
    25 April 2012

  3. Boceprevir for the treatment of genotype 1 chronic hepatitis C (TA253)

    Boceprevir is no longer available in the UK so this guidance has been withdrawn.

    Technology appraisal guidance
    Published
    25 April 2012

  4. Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)

    Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    22 September 2010
    View recommendations

    Sections for TA200

  5. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

    Clinical guideline
    Published
    24 February 2010
    View recommendations

    Sections for CG93

  6. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA173

  7. Entecavir for the treatment of chronic hepatitis B (TA153)

    Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.

    Technology appraisal guidance
    Published
    27 August 2008
    View recommendations

    Sections for TA153

  8. Telbivudine for the treatment of chronic hepatitis B (TA154)

    Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.

    Technology appraisal guidance
    Published
    27 August 2008
    View recommendations

    Sections for TA154

  9. Drug misuse in over 16s: psychosocial interventions (CG51)

    This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

    Clinical guideline
    Published
    25 July 2007
    View recommendations

    Sections for CG51

  10. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

    Technology appraisal guidance
    Published
    22 February 2006
    View recommendations

    Sections for TA96

  11. The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C (TA14)

    This guidance has been replaced by NICE technology appraisal guidance 75.

    Technology appraisal guidance
    Published
    28 October 2000

  12. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued [GID-TAG456]

    Technology appraisal guidance
    Discontinued